Marybeth S Hughes

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Sadik H. Kassim, M. Raffeld, S. Rosenberg, 2014, Clinical Cancer Research.

Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine1

S. Rosenberg, R. Morgan, M. Hughes, 2005, The Journal of Immunology.

Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

Seth M Steinberg, S. Steinberg, S. Rosenberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009, Blood.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

M. Raffeld, S. Rosenberg, R. Morgan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.